
Eraglusib Combo Improves Survival in Metastatic Pancreatic Cancer
Eraglusib in combination with gemcitabine and nab-paclitaxel achieved statistical significance in the first-line treatment of metastatic pancreatic ductal adenocarcinoma, according to data from the part 3B phase 2 Actuate-1801 trial which were shared in a …